LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Joint Statement on Horizon Europe

20/04/2019
POSITION PAPER

Joint Statement on Horizon Europe

Health industries welcome unprecedented progress leading to an adoption of Horizon Europe, its areas for missions and partnerships.

The six undersigned European health industry associations representing small and large companies welcome the Council and the European Parliament agreement on the Horizon Europe legislation, including areas for partnerships and missions, which clearly demonstrates Europe’s commitment to research and innovation.

We welcome the overall structure and ambition of Horizon Europe. Europe has been at the forefront of life science research and a health mission is a palpable signal that it intends to keep on striving for excellence and impact. The challenges identified in the Horizon Europe “Health” cluster, with activities across the whole research and innovation spectrum, are centred on relevance and impact for patients and society.

The text agreed allows our sectors to remain ambitious about a healthier future for European citizens, based on medical innovation, timely access to quality health interventions, better health outcomes for patients, and cost-effective healthcare. It is imperative for Europe to offer an attractive environment for research intensive industries, with the potential to bring innovative solutions to care givers and patients and boost local economies and growth.

We support the mission on cancer as this reflects the significance of this disease area as well as the importance of health research and investment in Europe. This mission will require a diversity of approaches and activities, and we expect that an Institutional Partnership for health research and innovation will significantly contribute to the mission objectives and activities. Our industries are supportive of the concept of both instruments as a very concrete recognition of the importance of R&D to improve the quality of life of European citizens and patients and boost the translational research power in Europe.

Our associations joined forces to prepare for a novel Institutional cross-sectorial Partnership for health research and innovation, breaking down the silos between different industries to accelerate the development of people-centred health care innovations for unmet public health need. We believe that the Horizon Europe legislation lays down a solid ground for such a partnership and will allow us to work towards our ambition to deliver tools, data and platforms, technologies and processes for innovative products and services for the benefit of citizens and patients. This will help us focus on learning healthcare systems predicting real needs; optimising the health journey for patients and de-risking innovation by providing solutions enhancing predictability.

Delivering on this promise depends however on an adequate budget that aligns with the level of Europe’s research ambition. We therefore call on the Council and the European Parliament to secure an ambitious budget for Horizon Europe in the Multiannual Financial Framework 2021-2027 to ensure that Europe continues to invest as a priority in research and innovation, contributing to economic growth in Europe.

COCIR: European Coordination Committee of the Radiological, Electromedical and Healthcare IT industry, www.cocir.org
EBE: European Biopharmaceutical Enterprises, www.ebe-biopharma.eu
EFPIA: European Federation of Pharmaceutical Industries and Associations, www.efpia.eu
EuropaBio: European Associations for Bioindustries, www.europabio.org
MedTech Europe: European Association of medical technology industries comprising medical devices, diagnostics and digital health, www.medtecheurope.org
Vaccines Europe: www.vaccineseurope.eu

Download the file below to read the full Position Paper.

Joint Statement on Horizon Europe


Download
2019_04_H_PP_Joint-Statement_HorizonEuropeDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

11/07/2025

Industrial Decarbonisation Accelerator Act – EuropaBio Position


Read more
07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more

Important links

  • Industrial Decarbonisation Accelerator Act – EuropaBio Position
  • EuropaBio Position on the Critical Medicines Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.